Merck & Cohas reported a surge in third quarter net income, based on strong sales of key drugs, including Januvia, Janumet and Gardasil.

Diabetes medications Januvia and Janumet reported sales increases of 41% and 42% respectively over the corresponding 2010 results, amounting to sales figures of $846m and $350m.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Sales of Singulair, Merck’s leading asthma/allergic rhinitis treatment, rose 10% to $1.34bn, and it remains the company’s best-selling drug.

Company sales reached $12.02bn, representing an 8% increase, owing to a 5% boost from foreign exchange.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now